Crescent Biopharma (CBIO) Receivables (2015 - 2025)
Crescent Biopharma (CBIO) posted quarterly Receivables of $18.0 million for Q4 2025, up 13079.09% year-over-year from N/an in Q4 2024, and up 13079.09% quarter-over-quarter from $136580.0 in Q4 2024.
Crescent Biopharma (CBIO) Receivables (2015 - 2025) Analysis & Trends
Crescent Biopharma (CBIO) has reported Receivables for 3 consecutive years, with $18.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables rose 13079.09% year-over-year to $18.0 million; the TTM figure through Dec 2025 stood at $18.0 million (up 13079.09% YoY), while the FY2025 annual figure was $18.0 million, up 13079.09% from the prior year.
- Receivables improved to $18.0 million in Q4 2025 per CBIO's latest filing, from $136580.0 in the prior quarter.
- Across five years, Receivables topped out at $18.0 million in Q4 2025 and bottomed at $136580.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.00 Mn |
| Dec 31, 2024 | 136,580.00 |
| Jun 30, 2015 | 20.00 Mn |